Presentation Detail
Speaker
Sungwon Lim, PhD, CEO & Co-Founder of ImpriMed, Inc.
Kevin Choy, BS, BSc, MS, DACVIM (Oncology)
Synopsis
In this presentation, Dr. Kevin Choy, a board-certified medical oncologist at Seattle Veterinary Specialists Blue Pearl, shares his experiences using ImpriMed in clinical practice over the past 2 years. By ordering ImpriMed’s drug response predictions, veterinarians see which anticancer drugs are most likely to achieve positive clinical outcomes for each specific canine lymphoma patient from the get-go. Dr. Choy finds the ImpriMed platform to be useful in both naive and relapsed settings to refine his chemotherapy protocols.Included in the ImpriMed diagnostic assay is also comprehensive lymphoma phenotyping via combination of both flow cytometry and PARR (clonality assay), which together with drug response predictions help veterinarians make informed chemotherapy selection decisions to help treat canine lymphoma with increased confidence, saving client’s resources and time.
